Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Live Attenuated Influenza Vaccine: Mucosal and Systemic Immune Responses in Adolescents
ChiCTR2500110151Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quadrivalent live attenuated influenza vaccine in influenza, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Serum IgG antibody level against vaccine strain at Day 28 and Nasal sIgA antibody level against vaccine strain at Day 28. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
quadrivalent live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on ChiCTR2500110151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110151.